WhARIO: whole-slide-image-based survival analysis for patients treated with immunotherapy-Reference-Cited by-同舟云学术

WhARIO: whole-slide-image-based survival analysis for patients treated with immunotherapy

Published:2024-05-11 Issue:03 Volume:11 Page:
ISSN:2329-4302
Container-title:Journal of Medical Imaging
language:
Short-container-title:J. Med. Imag.

Author:

Tourniaire Paul¹,Ilie Marius²,Mazières Julien³,Vigier Anna⁴,Ghiringhelli François⁵,Piton Nicolas⁶,Sabourin Jean-Christophe⁶,Bibeau Frédéric⁷,Hofman Paul²,Ayache Nicholas¹,Delingette Hervé¹

Affiliation:

1. Université Côte d’Azur, Inria, Epione Project-Team, Sophia Antipolis, Nice, France

2. Pasteur Hospital, Université Côte d’Azur Nice, Laboratory of Clinical and Experimental Pathology, Nice, France

3. CHU Toulouse-Hôpital Larrey, Université Paul Sabatier, Department of Pneumology, Toulouse, France

4. IUCT-Oncopole, Department of Pathology, Toulouse, France

5. Centre Georges-François Leclerc, Department of Medical Oncology, Dijon, France

6. Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U124, Department of Pathology, Rouen, France

7. Centre Hospitalier Universitaire de Besançon, Department of Pathology, Besançon, France

Publisher

SPIE-Intl Soc Optical Eng

Reference43 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

3. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

4. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

5. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry